Neutrophil Extracellular Traps (NETs) Promote Macrophage Inflammation and Impair Atherosclerosis Resolution in Diabetic Mice

Tatjana Josefs¹*, Tessa J. Barrett¹*, Emily Brown¹, Alexandra Quezada¹, Xiaoyun Wu², Maud Voisin³, Jaume Amengual², Edward A. Fisher¹,3

¹Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York
²Department of Food Science and Human Nutrition, University of Illinois Urbana Champaign, Illinois
³Department of Microbiology, New York University School of Medicine, New York, New York

* Equal contributions

Corresponding Author:
Edward A. Fisher, MD, PhD
NYU School of Medicine, New Science Building 705
435 East 30th St., NY, NY 10016
edward.fisher@nyumc.org

Running Title: NETs impair atherosclerosis resolution in diabetes
Word Count: 5808
Number of Figures: 5
Number of Tables: 1
Supplemental Figures: 2

Subjects Codes: Inflammation; Cardiovascular Disease; Diabetes, Type2; Atherosclerosis
Abstract

Neutrophil extracellular traps (NETs) promote inflammation and atherosclerosis progression. NETs are increased in diabetes and impair the resolution of inflammation during wound healing. Atherosclerosis resolution, a process resembling wound healing, is also impaired in diabetes. Thus, we hypothesized that NETs impede atherosclerosis resolution in diabetes by increasing plaque inflammation. Indeed, transcriptomic profiling of plaque macrophages from NET positive and negative areas in low-density lipoprotein receptor-deficient (Ldlr⁻/⁻) mice revealed inflammasome and glycolysis pathway upregulation, indicating a heightened inflammatory phenotype. We found that NETs decline during atherosclerosis resolution, which was induced by reducing hyperlipidemia in non-diabetic mice, but they persist in diabetes, exacerbating macrophage inflammation and impairing resolution. In diabetic mice deoxyribonuclease 1 (DNase1) treatment reduced plaque NETs content and macrophage inflammation, promoting atherosclerosis resolution after lipid-lowering. Given that humans with diabetes also exhibit impaired atherosclerosis resolution with lipid-lowering, these data suggest that NETs contribute to the increased cardiovascular disease risk in this population and are a potential therapeutic target.
**Introduction**

Cardiovascular disease (CVD) and diabetes are both associated with leukocytosis (1, 2). We and others have previously reported that hyperglycemia in mice impaired the resolution of atherosclerosis after lipid-lowering (3, 4). Hyperglycemia also stimulated myelopoiesis in the mice, which increased circulating levels of monocytes and neutrophils and their entry into plaques (5-7). While the contribution of monocyte-derived macrophages to atherogenesis has been extensively studied, less is known about neutrophils. Accumulating evidence indicates that neutrophils are also important protagonists in plaque progression (8). Their ability to form neutrophil extracellular traps (NETs) (9), structures found in human and mouse plaques (10-12), is of increasing interest in the context of atherogenesis due to the proinflammatory nature of NETs (13).

First reported in 2004 (14), NETosis is a process in which, in response to pathogens and sterile inflammatory stimuli, neutrophils release cytosolic and nuclear material forming a net-like extracellular structure (15). Relevant to atherogenesis, stimulators of NETosis include cholesterol crystals, oxidized low-density lipoprotein, oxysterols, platelets, and various chemokines (9). NETosis is not only stimulated by inflammation but can also promote it (9), for example, by increasing monocyte recruitment to inflamed sites and triggering macrophages to release reactive oxygen species and proinflammatory cytokines (16). The effects of NETs on plaque macrophages are thought to involve activation of their inflammasomes, but direct evidence in vivo to support this is scant (17).

In mice, genetic and pharmacological inhibition of NETosis reduces plaque size, inflammation, and features of instability (10, 18). In humans, circulating NET biomarkers positively correlate with atherosclerotic plaque size, and are independently associated with clinical severity of CVD and the incidence of major adverse cardiac events (19, 20). One clinical population in which NETs are hypothesized to be particularly atherogenic is those with diabetes. Compared to people without diabetes, those with diabetes exhibit increased CVD risk and impaired atherosclerosis resolution, or plaque regression, after lipid-lowering therapy (21, 22). That NETs could be an
important basis of these findings is supported by studies in which circulating NET biomarkers are correlated with both CVD and diabetes severity (23). Factors promoting NETosis in diabetes include both neutrophilia, and hyperglycemia, which primes neutrophils for NET formation (24) and provides an increased substrate for NETosis, which is glucose dependent (25).

To date, CVD clinical studies have addressed the role of NETs only in the progression of atherosclerosis. Given that most patients, including those with diabetes, commence primary or secondary CVD prevention (typically lipid-lowering) after the formation of plaques, resolution of atherosclerosis is an important, and largely unmet, clinical goal. The information presented above suggested to us that the failure of lipid-lowering therapies to fully reduce CVD risk in patients with diabetes, or to maximally resolve atherosclerosis in mice and patients with diabetes (reviewed in (26-28)), represented adverse consequences of the increased plaque level of NETs in this metabolic setting (25). This phenomenon would be similar to NETs impairing wound healing in diabetes (24).

Thus, we have investigated the effect of NETs on atherosclerosis resolution in mice with and without diabetes, using deoxyribonuclease 1 (DNase1) as a tool to deplete NETs from plaques (as in (10)). NETs had a direct proinflammatory influence on plaque macrophages, while DNase1-mediated depletion was associated with dampening of macrophage inflammation and improved atherosclerosis resolution after lipid-lowering despite ongoing hyperglycemia. Given that DNase1 has approved applications in other human diseases (e.g., cystic fibrosis), the results also suggest a new mechanistic approach to improving atherosclerosis resolution in high-risk patients with diabetes, which remains an important clinical goal.
Results

NET formation is associated with a proinflammatory macrophage phenotype

Although NETs have been associated with macrophage activation and potentiating plaque formation (10), their molecular effects on plaque macrophage phenotype in vivo have not been directly determined. To address this gap, we collected macrophages (CD68+ cells) in NET positive (NET+) and NET negative (NET-) atherosclerotic plaque areas (Figure 1A, Supplemental Figure 1A) by laser capture microdissection (LCM) in Ldlr<−<− mice after 16 weeks of western diet feeding. Collected macrophages provided material for profiling by RNA sequencing to characterize the phenotypical features of macrophages in NET+ areas in atherosclerotic plaques (Figure 1B, C).

Consistent with a proinflammatory phenotype, glycolysis and inflammasome pathways were enriched in macrophages isolated from NET+ areas relative to those in NET- regions (Figure 1D, E). Confirmation of inflammasome activation was achieved by immunohistochemical staining for NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) and caspase-1, and quantification of their localization in NET+ versus NET- macrophage regions (Figure 1F). Inflammasome activation was found to be significantly associated with macrophages present in NET+ areas (P = 0.03, Figure 1G). In addition to the enrichment in inflammasome-related genes in the NET+ areas, the enrichment of glycolytic markers also indicates a switch to a proinflammatory M1-like macrophage phenotype (29). Indeed, based on standard markers, the CD68+ cells from NET+ vs. NET- areas were enriched in M1 (3.6-fold increased, inducible nitric oxide synthase (inos)), and suppression of M2 (2-fold decrease (Cd206)) characteristics. Further, immunofluorescence staining of iNOS confirmed increased proinflammatory macrophages in NET+ plaque areas (P=0.055, Figure 1H).

To exclude the possibility that the RNA from CD68+ cells selected from NET+ areas was contaminated by neutrophil RNA, we compared the reads for CD68 to that of the neutrophil markers lymphocyte antigen 6 complex locus G6D (Ly6g), myeloperoxidase (Mpo) and neutrophil elastase (Ne). Counts for Cd68 were 7500-fold greater than that of neutrophil transcripts, confirming the specificity of our approach (Supplemental Figure 1B). Additionally, to exclude the
possibility of significant contamination with vascular smooth muscle cells (VSMCs), which can take on characteristics of macrophages when cholesterol-loaded in vitro (30) or in atherosclerotic plaques (31-33), we compared the transcript expression of Cd68 to the myeloid-specific transcript Ptpc (Cd45) and the smooth muscle cell markers myosin heavy chain-11 (Myh11) and calponin 1 (Cnn1) using the expression values from RNA seq data obtained in the present study, and in primary murine bone marrow-derived macrophage (BMDMs) and murine vascular SMCs. As shown in Supplemental Figure 1C, the Cd45/Cd68 ratio was comparable between the laser captured CD68+ cells and BMDMs, whereas Cd45 was undetectable in murine vascular SMCs. Further, compared to laser captured CD68+ cells, the Myh11/Cd68 and Cnn1/CD68 ratios are approximately 12-fold higher in vascular SMCs. Overall, these data show that the data in Figure 1 are not confounded to a significant extent by contamination by other cell types and provide further support that NETs skew macrophages towards a proinflammatory phenotype in atherosclerotic plaques.

Clearing NETs can overcome impaired atherosclerosis resolution in diabetic mice

Neutrophils isolated from diabetic mice and humans are more prone to form NETs, with NET formation leading to impaired wound healing (24). We have also shown that even with lipid-lowering, maximal atherosclerosis resolution requires reduced macrophage inflammation (34). Thus, we hypothesized that the expected increase in plaque NETs in diabetic mice would impair atherosclerosis resolution due to their proinflammatory effects on macrophages (Figure 1), and that resolution in diabetic mice would improve by reducing NETs.

To test this, Ldlr/- mice were fed a Western diet for 16 weeks to generate advanced atherosclerotic lesions, and atherosclerosis resolution was induced, as in a previous study (5), by feeding the mice a chow diet for four weeks, which resulted in decreased plasma lipid levels (Figure 2A; Table 1). A subset of mice were made diabetic by injection of streptozotocin (STZ). Since NETs are predominantly degraded by exonucleases (35), mice received DNase1 or vehicle injections every other day during the resolution period. In total, we compared baseline (mice
sacrificed after 16 weeks on a western diet) and four regression groups: control, control + DNase1, STZ-induced diabetes, and diabetes + DNase1.

Neither STZ nor DNase1 affected total plasma cholesterol levels in the four resolution groups, with the levels in each significantly reduced when compared to baseline mice (Table 1). Plasma glucose levels were increased in the STZ groups only (Table 1). To evaluate NET content, we performed standard NET staining (MPO, Citrullinated histone H3 (H3Cit) and the neutrophil marker Ly6G; Figure 2B) and quantified NETs as % plaque area (Figure 2C). Strikingly, in the non-diabetic mice, we observed a decrease in total plaque NETs area in the control and DNase1 resolution groups versus baseline (5.7% vs. ~1.5% of plaque area), showing that NETs can resolve spontaneously in a non-hyperlipidemic environment. As expected, NETs did not resolve spontaneously in hyperglycemic conditions, but, notably, we observed a substantial decrease in NET content in the diabetes + DNase1 group (7.0% vs. 2.3% of plaque area, or a 68% reduction).

To determine if NETs content correlated negatively with atherosclerosis resolution, CD68+ macrophages were quantified and represented as the percentage of plaque area (%CD68; Figure 2D-E). As expected, we found a significant decrease in lesion %CD68 in control mice compared to the baseline group (43.6 % vs. 24.1 %). Atherosclerosis resolution was unchanged in control mice receiving DNase1, consistent with the spontaneous loss of NETs in those mice. In diabetic mice, the reduction of %CD68 immunostaining was impaired (43.6 % vs. 35.2 %), as expected (3). Notably, DNase1 treatment in diabetic mice showed significantly enhanced atherosclerosis resolution (35.2 % vs. 23.0 %), which was comparable to that of control mice.

To determine the relationships among the relative contributions to plaque characteristics by macrophages (above), extracellular matrix (as assessed by collagen) and necrotic core, additional plaque analyses were performed. As shown in Figure 3A, there was a significant reduction in plaque size in all of the resolution groups (Figure 3A) compared to baseline. Collagen content tended to increase relative to baseline, with statistical significance achieved in the resolution control group (Figure 3B). The necrotic core plaque areas were found to be similar in the baseline
and the diabetes resolution groups, and significantly lower in the other resolution groups, including DNase1 treated diabetic mice (Figure 3C).

**DNase1 treatment reduces NET-induced plaque macrophage inflammation and promotes atherosclerosis resolution in diabetic mice**

The results in Figure 2 showed DNase1 treatment was able to overcome the impairment of atherosclerosis resolution by diabetes. Because a prominent feature of macrophages in NET+ areas is the induction of the inflammasome and other metabolic and transcriptomic changes characteristic of inflammation (Figure 1), we hypothesized that the benefits of NET clearance in diabetic mice (Figure 2) were associated with a reduction in the inflammatory phenotype of plaque macrophages. Consistent with this, the percentage of macrophages associated with plaque NETs was significantly decreased by 90%, from 2.7 to 0.3% in the DNase1 treated diabetic mice compared to diabetic mice with no treatment (Figure 4A-B). To support this hypothesis more directly, we performed immunofluorescence staining for the inflammasome markers NLRP3 and Caspase-1 (Figure 4C). Indeed, NLRP3 and caspase-1 positive cells were significantly increased in diabetic mice, compared to the control group, and decreased with DNase1 treatment. Additionally, the increase in plaques of diabetic mice of the inflammatory macrophage marker iNOS was reversed with DNase1 treatment (Figure 4D). As we previously reported (6, 7), there was a significant increase in circulating neutrophils in diabetes. There was also a trend towards increased plaque neutrophils (Supplemental Figure 2A,B), with a suggestion that DNase1 reduced both increases.

Cholesterol crystals have been shown to be an inflammasome activator in atherosclerosis (36). Thus, we examined whether they were associated with the macrophage inflammation we observed and if DNase1 treatment affected their plaque content. Cholesterol crystals in atherosclerotic plaques were detected using polarized light (Figure 5A). As shown in Figure 5B, in the resolution groups, the cholesterol crystal content was ~70% greater (P = 0.01) in the diabetes (2.2%) vs. control mice (1.3%). Interestingly, cholesterol crystals tended to be decreased in the diabetes + DNase1 compared to diabetes group (P = 0.06).
Discussion

NETs are found in human and mouse plaques, and in mice are associated with increased atherosclerosis progression (10-12). They have also been shown to impair wound healing in diabetic mice (24). Though considered to be generally inflammatory, how NETs contribute to macrophage activation is incompletely understood (17). The present study addresses this gap in knowledge. By isolation of macrophages from NET positive and negative plaque areas, we identify that NETs induce a proinflammatory “M1-like” macrophage phenotype, as evidenced at the molecular level by enriched transcripts characteristic of glycolysis and inflammasome activation and at the protein level by increases in relevant immunohistochemical markers. We also detected enhanced NET presence in diabetic plaques, consistent with a study in non-atherosclerotic mice that diabetes primes neutrophils for NET production (24).

The NET-macrophage interaction is a likely contributing factor to persistent macrophage inflammation in the plaques of diabetic mice even after lipid-lowering. This is supported by our current study, which finds a reduction in plaque inflammation and proinflammatory macrophages in lesions of diabetic mice following the degradation of NETs with DNase1 in conjunction with lipid-lowering. Further, we provide evidence that the resolution of plaque NETs in diabetic mice promotes a more stable appearance, as noted by a decrease in plaque necrotic area following DNase1 treatment. These data are consistent with the association between NET formation and human plaque instability (12, 37).

DNase1 reduces NETs by degradation of the chromatin fibers that comprise their backbone (14), which usually, but not always, reduces inflammation and disease severity in several models (38). Based on the results in the present study, we can add the resolution of atherosclerosis in diabetes to the list of conditions that are improved by reducing NET content. In addition to the direct
effects in plaques by the reduction of NETs (e.g., reduced inflammasome activation in plaque macrophages), there are probably indirect benefits as well. For example, inflammation in plaques also increases neutrophil recruitment, further amplifying inflammation (39). This reasoning likely provides the logical link between the reduction in plaque inflammation in diabetic mice (Figure 4) with the data suggesting that the increased circulating and plaque neutrophil levels in the diabetic mice were partially suppressed by DNase1 treatment (Supplemental Figure 2).

The present results showing a powerful effect of NETs on macrophage inflammasome activation led us to consider this finding in the context of another mediator of inflammasome activation in atherosclerosis, namely cholesterol crystals (36). The current understanding is that the inflammasome pathway requires two signals for full activation. Warnatsch et al. (10) have shown that NETs are a priming cue, with the second signal being cholesterol crystals (9). Furthermore, crystal formation and inflammasome activation were recently shown by Westerterp et al. to be promoted by reduced cholesterol efflux via ATP-binding cassette transporter A1/G1 (ABCA1/ABCG1) (40). Additionally, cholesterol crystals are not only the second signal for inflammasome activation, but they also stimulate NETosis (10).

As shown in Figure 5, cholesterol crystals were increased in diabetic mice relative to the other resolution groups, which is consistent with hyperglycemia reducing cholesterol efflux in macrophages and their precursors by decreasing ABCA1/ABCG1 expression (e.g., (6, 7)). Taken together, our and the published data imply that cholesterol crystals could play a dual role in atherosclerosis, namely to promote NETosis, which provides multiple priming cues (first signals) for macrophage inflammasome activation, and also to serve as the second signal to complete the activation process in the primed macrophages. DNase1 treatment, by clearance of NETs, would reduce both types of macrophage inflammasome signals. This results in less macrophage inflammation, which we have shown is required to promote maximal atherosclerosis resolution after lipid-lowering (34).
In summary, we have shown for the first time the molecular impact of NETs on plaque macrophages, especially on their inflammasome and glycolytic pathways. We also show that NETs formed during atherosclerosis progression in non-diabetic mice can spontaneously resolve upon the correction of hyperlipidemia. In contrast, they persist in the setting of diabetes and impair atherosclerosis resolution, likely due to their activation of macrophages and exacerbation of the general inflammatory environment in the plaque. Notably, DNase1 was an effective treatment to improve atherosclerosis resolution in the face of ongoing hyperglycemia. Because the rate of CV disease remains higher in people with versus without diabetes after similar lipid-lowering, the results suggest not only a basis for this but also the therapeutic potential of NET reduction, especially in those whose diabetes is not well controlled.
Methods

Animals & Atherosclerosis Regression Study: Ldlr<sup>−/−</sup> mice (Jackson Laboratory) were fed western diet (0.3% cholesterol; Dyets Inc. D101977Gi) for 16 weeks (progression), followed by 4-weeks (regression) on chow diet. STZ (Sigma Aldrich, cat. S0130-500MG; 0.05mg/g body weight) or sodium citrate (control) was injected daily for 5 days intraperitoneal (i.p.) just prior to regression to induce diabetes, as described previously (7). During the four-week regression period, DNase1 (62.5µg/mouse Dornase Alfa, Genentech, Inc.) in 0.9% NaCl or 0.9% NaCl only (control) was injected i.p. every other day. At the day of sacrifice, mice were anesthetized via intraperitoneal (i.p.) injection of ketamine (100mg/kg) and xylazine (10mg/kg). Blood was collected via cardiac puncture in EDTA-containing tubes and mice perfused with 10% sucrose in saline solution (0.9% NaCl). Collected aortic roots were embedded in optimal cutting temperature (OCT) compound and frozen at -80°C. All procedures were conducted under NYU Animal Care and Use Committee approved protocol #160725 (Creating glucose-responsive cardiovascular complications in the mouse).

Plasma Lipid and Glucose Measurements: Total cholesterol was measured using Total Cholesterol E Kit (Wako Life Science, cat. NC9138103). Plasma glucose levels were determined using the Contour Blood Glucose Monitoring System (Bayer).

Flow Cytometry: Total white blood cell counts were measured from freshly collected mouse blood using a hematology cell counter (Oxford Science Inc.). Red blood cells were lysed with buffer (Sigma-Aldrich), and cells stained with CD45 Pe/Cy7 (BioLegend, Cat. 103114), CD115 PE (BioLegend, Cat. 135505), and APC Ly-6G/Ly-6C (Gr-1, BioLegend, Cat. 108412). Neutrophils were identified by flow cytometry using LSRII analyzer and analyzed using FlowJo v10.

Atherosclerotic Plaque Assessment: Serial sections (6µm thick) were stained for CD68 (rat antimouse CD68, Bio-Rad, Cat. MCA1957), as done before (34). Briefly, sections were fixed and permeabilized with 100% ice-cold acetone, blocked, and stained with a rat anti-mouse CD68
antibody (Bio-Rad, cat. MCA1957) followed by an incubation with a biotinylated rabbit anti-rat IgG secondary antibody (Vector Laboratories, cat. BA4000), and visualized using the Vectastain ABC kit (Fisher Scientific, Cat. NC9313719). Slides were counterstained with hematoxylin/eosin (Sigma), dehydrated in an ethanol gradient and xylene (Fisher Scientific, NH), and mounted with coverslips using Permount (Fisher Scientific). NETs were identified using colocalization immunofluorescence staining of Ly6G (BD Bioscience, cat. 551459), MPO (Abcam, cat. ab90812), and H3Cit (Abcam, cat. ab5103). Tissue was fixed in formalin, permeabilized using 0.5% Triton-X, followed by incubation of primary Ab o/n at 4°C and stained with the secondary antibodies for 2h (Thermo Fisher Scientific, cat. A21434 & A21245). The same protocol was used to stain for NLRP3 (Abcam, cat. ab4207) and caspase-1 (Millipore, cat. AB1871; secondary antibodies: Thermo Fisher Scientific, cat. A-11055 & A-31573). iNOS staining was done on formalin-fixed tissue, permeabilized using 0.05% Tween and 1% Triton-X, followed by incubation with a conjugated iNOS antibody (Abcam, cat. Ab209027) incubated o/n at 4°C. Collagen content was determined by Picosirius Red staining as done before (41). NETs and iNOS stainings were imaged using Hamatsu NanoZoomer 2.0; a Leica SP5 Confocal Microscope was used to obtain images of NLRP3 and caspase-1 staining. Collagen was visualized using polarized light microscopy (Zeiss Axio Observer). ImagePro Plus 7.0 software was used to determine plaque, CD68+, collagen and necrotic core areas. NET+ area, NLRP3+, Caspase1+, and iNOS+ cells were determined by Image J 1.51r. These data were then divided by the plaque area of the section to get the % positive for NETs or CD68. NET+ macrophages were calculated by dividing %CD68 by %NETs. NLRP3+, caspase-1+ and iNOS+ cells were divided by total cells (4ʹ,6-diamidino-2-phenylindole (DAPI) nuclear staining) to get %total cells.

Cholesterol crystal images were acquired using an Axioscan microscope (Carl Zeiss, Jena, Germany) using a 10x air objective. Cholesterol crystal images were captured using polarized light and represented as % plaque area.

**Laser Capture Microscopy and RNA-seq:** CD68+ cells were selected from plaques by laser capture microdissection (LCM) as previously described (42), and all LCM procedures were performed
under RNase-free conditions. Briefly, aortic root sections were stained with hematoxylin-eosin, and foam cells identified under a microscope and verified by positive CD68 staining. Following LCM, RNA was isolated using the PicoPure Kit (Molecular Devices, Inc., Sunnyvale, CA), treated with DNase and the quality and quantity determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). RNA was amplified (Automated Nugen Ovation Trio Low Input RNA (500pg)), sequenced (HiSeq 4000 Paired-End, Illumina), and sequencing results analyzed using Ingenuity Pathway Analysis (IPA; Qiagen). Cutoffs of -0.5 to 0.5 log2 fold change yielded 7337 analyses-ready molecules of which 4046 were down- and 3291 up-regulated in NET+ versus NET- areas. The data discussed in this report have been deposited in NCBI's Gene Expression Omnibus (43) and are accessible through GEO Series accession number GSE145200 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145200).

To obtain transcripts of bone-marrow derived macrophages (BMDM), bone marrow cells were isolated by flushing cells from the femurs and tibiae of wild-type C57BL6 mice. Cells were differentiated into BMDMs in 4.5 g/L glucose DMEM (Lonza) with 20% fetal bovine serum (FBS), 1% penicillin/streptomycin, and murine M-CSF (10 ng/mL; #315-02, PeproTech) at 37 °C and 5% CO₂ for 7 days. Cells were lysed with Buffer RLT (Qiagen) containing 10 % betamercaptoethanol and the Norgen Animal Tissue RNA Purification Kit (#25700, Norgen Biotek) was used to isolate RNA from cells. The Dynabeads mRNA Direct Purification Kit (#61011, ThermoFisher Scientific) was used to isolate mRNA transcripts using Poly-A selection, and cDNA synthesis was performed using SuperScript II Reverse Transcriptase (#18064014, ThermoFisher Scientific). Libraries were prepared from 50ng of each cDNA sample using the Nextera DNA library prep kit (#FC-121-1031, Illumina). Samples were sequenced on the Illumina HiSeq 2000 using 50 paired-end reads.

In the case of VSMC, cells were prepared from wild-type C57BL6 mice as in (44), and the RNA isolated and sequenced as described above.
**Statistics:** Data are expressed as mean ± SEM. Data were tested for normality and equal variance and analyzed by the appropriate parametric or non-parametric test in GraphPad Prism 7 as stated in each figure. P ≤ 0.05 was considered significant.
Author Contributions
T.J., T.J.B. and E.A.F. designed experiments. T.J. and T.J.B performed the experiments and analyses. E.B. assisted with the RNA seq analyses. A.Q. helped with the analysis performed in Figure 2. X.W. and J.A. performed cholesterol crystal visualization and quantification. M.V. added BMDM sequencing data. T.J., T.J.B., J.A., E.A.F wrote and edited the manuscript.

Acknowledgments
We appreciate the technical contributions of Yoscar Ogando and Felix Zhou. The RNA sequencing was done by the Genome Technology Center, a shared resource that is partially supported by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Permutter Cancer Center.

Funding was provided by American Heart Association (18PRE33990436, TJ; 18CDA34110203AHA, TJB, 16SDG27550012, JA), the American Society of Hematology (18-A0-00-1001884, TJB), and the NIH (HL147252, JA; and for EAF, TJ, TJB, R01 DK095684, R01 HL117226, R01 HL084312, R01 HL129433, P01 HL092969, and P01 HL131481).

Conflicts of Interest
Based on a review of the criteria of JCI Insight, the only author with a disclosure is Edward A. Fisher, who reports receiving income >$10,000 from being an expert witness on behalf of Amgen (PCSK9 antibodies) and Dr. Reddy’s Laboratories (eicosapentaenoic acid).
References


FIGURES and LEGENDS

Figure 1. Neutrophil extracellular traps (NETs) in atherosclerotic plaques skew macrophages to a proinflammatory phenotype.

(A) Representative atherosclerotic plaque section stained for neutrophil extracellular traps (NETs) as determined by colocalization of myeloperoxidase (MPO), the lymphocyte antigen 6 complex locus G6D (Ly6G), citrullinated histone H3 (H3Cit) and macrophages (CD68). CD68+ cells were collected via laser capture microdissection (LCM) in NET positive (NET+) and NET negative (NET-) areas and sequenced. Scale bar 100µm. (B) Heatmap and (C) volcano plot showing differential gene expression in NET+ versus NET- macrophages. (D) Upregulation of the glycolysis and (E) inflammasome pathways in NET+ compared to NET- macrophages determined.
using Ingenuity Pathway Analysis. (F) Immunofluorescence staining and (G) quantification confirming the inflammasome pathway activation (NLR family pyrin domain containing protein 3 (NLRP3^+), caspase1^+) in NETs+ area (bottom), scale bar 50µm. (H) Quantification of iNOS immunofluorescence staining showing an increase in iNOS in NET+ versus NET- Area (%DAPI). N=3-5/group, *P<0.05 using unpaired t-test.
Figure 2. DNase1 treatment promotes atherosclerosis regression in diabetic mice.

(A) Male Ldlr/− mice were fed a western diet for 16 weeks to develop baseline plaques. At week 15 a subset of mice received streptozocin injections to induce diabetes. At week 16 a subset of mice were harvested for baseline measures, and all other mice were switched to a chow diet to induce resolution of plaques. These mice were then split into 2 groups, and over a 4-week period received either DNase1 (62.5µg/mouse) or vehicle injections every other day. At week 20, mouse tissues were harvested for plaque analyses. (B) NETs staining and (C) quantification in aortic roots, as determined by composite staining of myeloperoxidase (MPO), the lymphocyte antigen 6 complex locus G6D (Ly6G) and citrullinated histone H3 (H3Cit); scale bar 100 µm. (D) Representative pictures and (E) quantification of CD68 staining as a marker of
plaque macrophage content. Scale bar 100 µm. Data are shown as mean ± SEM, N=7-12/group
*P<0.05, 1-way ANOVA with Tukey’s multiple comparison test.
Figure 3. Effects of DNase1 treatment on plaque size, collagen content, and necrotic area in atherosclerotic plaques.

More analyses of mice described in Figure 2: Quantification of (A) plaque size, (B) Sirius red staining to determine collagen content and (C) plaque necrotic area. Data are shown as mean ± SEM, N=4-12/group *P<0.05, ** P<0.005, *** P<0.001 1-way ANOVA with Dunnett’s multiple comparison test compared to the baseline (A,B) or diabetes (C) group.
Figure 4. DNase1 treatment promotes atherosclerosis resolution in diabetic mice by reducing NETs-induced plaque macrophage inflammation.

More analyses of mice described in Figure 2: (A) Overlapping NET (*left panel*) and CD68 staining (*right panel*) in diabetic mice versus diabetic mice treated with DNase1, scale bar 50µm. (B) Amount of macrophages (%) co-localized with NETs. (C) Quantification of NLRP3⁺, caspase-1⁺ cells, and, (D) iNos⁺ cells, all as % DAPI (4′,6-diamidino-2-phenylindole) staining of plaques.
Data are shown as mean ± SEM, N=3-5/group, *P<0.05, 1-Way ANOVA with Tukey’s multiple comparison test.
Figure 5. Effects of diabetes and DNAse1 treatment on cholesterol crystal content in resolving plaques.

More analyses of mice described in Figure 2: (A) Cholesterol crystal visualization (white), and (B) quantification (as % plaque area) in atherosclerotic plaques with DAPI (blue) as counterstain; scale bar 100µm. Data are shown as mean ± SEM, N=5-8/group, *P<0.05, 1-Way ANOVA with Tukey’s multiple comparison test.
Table 1.
Total plasma cholesterol and blood glucose levels (mg/dL, mean ± SD), n=5-13/group, 1-way ANOVA, * P<0.0001 compared to Baseline; ° P<0.0001 compared to Diabetes

<table>
<thead>
<tr>
<th></th>
<th>Cholesterol (mg/dL)</th>
<th>Blood Glucose (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>1000 ± 327.7</td>
<td>108.6 ± 32.3°</td>
</tr>
<tr>
<td>Regression</td>
<td>221.6 ± 71.1*</td>
<td>123.5 ± 31.3°</td>
</tr>
<tr>
<td>Regression + DNase1</td>
<td>216.4 ± 28.5*</td>
<td>175.0 ± 26.7°</td>
</tr>
<tr>
<td>Diabetes</td>
<td>325.1 ± 83.4*</td>
<td>450.5 ± 79.5</td>
</tr>
<tr>
<td>Diabetes + DNase1</td>
<td>323.3 ± 96.4*</td>
<td>453.8 ± 99.1</td>
</tr>
</tbody>
</table>